文献速递肝病消化道肿瘤与早癌

不稳定性再代偿:HBV相关失代偿期肝硬化的中间亚型

Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2025-10-28

该研究基于两个队列纳入378例HBV相关失代偿期肝硬化患者,按Baveno VII标准将再代偿分为稳定型和不稳定型。中位随访5.3年,稳定再代偿占53.4%,不稳定再代偿占24.3%;不稳定组5年HCC或全因死亡率高于稳定组(14.7% vs 10.1%,p=0.038),但低于持续失代偿组。

要点

  • 再代偿并非均一状态,应进一步分为稳定型和不稳定型。
  • 不稳定再代偿5年HCC或全因死亡率高于稳定再代偿。
  • 不稳定再代偿预后仍优于持续失代偿患者。

核心结论

  • 再代偿不是单一状态,应进一步亚分类;不稳定再代偿是独立状态,生存劣于稳定再代偿但优于持续失代偿。

研究设计与样本

  • 从两个队列纳入符合条件的HBV相关失代偿期肝硬化患者,首次失代偿后每6个月评估临床特征和并发症,随访至5年。
  • 共纳入378例患者,再代偿按Baveno VII标准定义,并分为稳定(后续无失代偿)和不稳定(复发失代偿或多次失代偿事件后再代偿)。

主要发现

  • 378例中294例(77.8%)达到再代偿,84例(22.2%)未达到。
  • 中位随访5.3年(IQR 4.4-5.8)后,稳定再代偿202/378例(53.4%),不稳定再代偿92/378例(24.3%)。
  • 不稳定组5年HCC或全因死亡率高于稳定组(14.7% vs. 10.1%,p = 0.038),但低于持续失代偿患者。
  • 不稳定组肝功能改善程度介于稳定再代偿和持续失代偿之间。
  • 逻辑回归预测再代偿的AUROC为0.884,支持向量机预测稳定再代偿的AUROC为0.911。

关键数值与推荐

  • 再代偿定义依据Baveno VII标准。
  • 稳定再代偿定义为后续无失代偿,不稳定再代偿定义为复发失代偿或多次失代偿事件后再代偿。

临床怎么用

  • 对HBV相关失代偿期肝硬化达到再代偿者,应进一步区分稳定与不稳定亚型以评估预后。
  • 不稳定再代偿患者需加强HCC监测和随访管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Recent studies show that patients with hepatitis B virus (HBV)-related decompensated cirrhosis who achieve recompensation can still experience further decompensation, suggesting that recompensation status can change over time. This study aimed to classify patterns of recompensation and charaterize the clinical differences among these subgroups. METHODS: Eligible patients with HBV-related decompensated cirrhosis were enrolled from two cohorts. Clinical characteristics and complications were assessed every 6 months for up to 5 years following their first episode of decompensation. Recompensation was defined according to the Baveno VII criteria and further categorised as stable (no subsequent decompensation) or unstable (recurrent decompensation or recompensation following multiple decompensation episodes). RESULTS: A total of 378 patients were included; 294 (77.8%) achieved recompensation, while 84 (22.2%) did not. After a median follow-up of 5.3 years (IQR 4.4-5.8), recompensated patients were classified into stable recompensation (202/378, 53.4%) and unstable recompensation (92/378, 24.3%). The 5 year rate of hepatocellular carcinoma (HCC) or all-cause mortality was higher in the unstable group than the stable group (14.7% vs. 10.1%, p = 0.038), yet remained lower than in patients with ongoing decompensation. Liver function improvement was intermediate in the unstable group compared with the stable recompensation and ongoing decompensation. Logistic regression yielded the highest accuracy for predicting recompensation (AUROC = 0.884), while support vector machine algorithms best predicted stable recompensation (AUROC = 0.911). CONCLUSION: Recompensation is not a uniform condition and should be further subclassified. Unstable recompensation is a distinct state with poorer survival than stable recompensation, yet better outcomes than ongoing decompensation.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Xia S, He Z, Wu X, et al. Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis. Aliment Pharmacol Ther. 2025. PMID: 41147778. doi:10.1111/apt.70430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。